Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126646 · ClinicalTrials.gov registry record · Phase 1
BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00126646 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 24 participants.
The verdict
NCT00126646, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: BL22 immunotoxin can find tumor cells and kill them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of BL22 immunotoxin in treating patients with refractory B-cell chronic lymphocytic leukemia, prolymphocytic leukemia, or non-Hodgkin's lymphoma.
Interventions
- DRUG BL22 immunotoxin
- PROCEDURE antibody-drug conjugate therapy
- PROCEDURE immunotoxin therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00126646
The ClinicalTrials.gov registry entry for NCT00126646 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BL22 immunotoxin is the first listed.
NCT00126646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00126646 about?
NCT00126646 is a clinical study titled "BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma". RATIONALE: BL22 immunotoxin can find tumor cells and kill them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of BL22 immunotoxin in treating patients with refractory B-cell chronic lymphocytic leukemia, prolymphocytic leukemia, or non-Hodgkin's...
What is the current status of trial NCT00126646?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2005-06. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00126646?
The interventions under investigation include: BL22 immunotoxin (DRUG), antibody-drug conjugate therapy (PROCEDURE), immunotoxin therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00126646?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.